BFR (bendamustine, fludarabine, and rituximab) allogeneic conditioning for chronic lymphocytic leukemia/lymphoma: reduced myelosuppression and GVHD

Myelosuppression, graft-versus-host disease (GVHD), and relapse remain major causes of morbidity after stem cell transplantation for relapsed lymphoma. In this phase 1/2 study, we tested the safety and efficacy of escalating doses of bendamustine (70, 90, 110, and 130 mg/m(2) per day for 3 days), co...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Blood
Main Authors: Khouri, Issa F., Wei, Wei, Korbling, Martin, Turturro, Francesco, Ahmed, Sairah, Alousi, Amin, Anderlini, Paolo, Ciurea, Stefan, Jabbour, Elias, Oran, Betul, Popat, Uday R., Rondon, Gabriela, Bassett, Roland L., Gulbis, Alison
Formato: Artigo
Idioma:Inglês
Publicado em: American Society of Hematology 2014
Assuntos:
Transplantation
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC4260365/
https://ncbi.nlm.nih.gov/pubmed/25145344
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood-2014-07-587519
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados